Navigation Links
Novel virus entry mechanism could lead to new drugs against poxviruses

Research published in the Proceedings of the National Academy of Sciences on 11 April describes how the Imperial College London team discovered the mechanism allowing Vaccinia virus to shed its outer lipid membrane and enter cells. The mechanism is unique in virology and paves the way for development of new antiviral drugs.

Many viruses, such as influenza, are surrounded by a single lipid membrane, or envelope, and to enter cells this membrane must be removed. Previously, all enveloped viruses were thought to shed their lipid membrane by fusion with a cell membrane which allows the virus core to be released into the cell.

In contrast, the extracellular form of Vaccinia virus has two lipid membranes, meaning a single fusion event will not release a naked virus core into the cell. The researchers found that interactions between polyanionic or negatively charged molecules on the cell surface and glycoproteins on the virus particle caused a non-fusogenic disruption of the virus outer envelope, allowing the poxvirus to enter the cell.

As well as discovering how the double membrane problem is solved, the researchers demonstrated that polyionic compounds can be used to treat poxvirus infections, even days after infection has started. Disrupting the outer membrane with polyanionic compounds exposes the virus, allowing antiviral antibodies to be more effective. The disruption of the outer membrane also limits the spread of the virus in the body.

Professor Geoffrey L. Smith FRS, from Imperial College London and a Wellcome Trust Principal Research Fellow, said: "This work has uncovered a completely novel biological process. It increases our understanding of how viruses can manipulate biological membranes and will help the development of new drugs against poxviruses, such as variola virus, the cause of smallpox."


'"/>

Source:Imperial College London


Page: 1

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology: